Myopia Profile

Atropine.

The past five years has seen research and clinical practice focus on low-concentration atropine (0.01% to 0.05%) which appears to provide dose-related efficacy with minimal side effects, compared to higher concentrations. 

The use of topical atropine for myopia control has decades of clinical and research history, but recent research has explored low concentrations, different formulations, and whether combination with optical treatments can boost myopia control results. New, preservative-free formulations are now superseding compounded preparations in scientific studies and adding to the story on the ideal concentration and target populations.

Follow the links on this page to learn more about atropine for slowing myopia progression.

See all myopia control products

Atropine articles in Myopia Profile

When to prescribe Atropine for myopia controlAtropine as a first line treatment. Contact lens options likely provide the best option to both correct myopia and control progression as a monotherapy.Read Full Article Determining the Optimal Concentration of AtropineSignificant controversy exists in both literature and clinical optometric practice regarding the optimal concentration of atropine.Read Full Article Combination atropine treatments: when more is moreAtropine is a treatment for myopia control, but do combination treatments such as with orthokeratology increase the efficacy?Read Full Article
When to prescribe Atropine for myopia controlAtropine as a first line treatment. Contact lens options likely provide the best option to both correct myopia and control progression as a monotherapy.Read Full Article

Enormous thanks to our visionary sponsors

Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.